Major Depressive Disorder

Three new trials suggest a novel antidepressant hides inside the blue-skinned fruit.

Imagine working with a young patient showing signs of psychosis for the past 6 weeks. Your initial assessment appears to rule out medical- or substance-induced etiologies, yet symptoms persist. What's a psychiatrist to do?

When concern for a patient is not so severe that a clinician feels compelled to call the police, there are options.

As a discipline, emergency psychiatry has widened its role, especially following the enormous mental health fallout from the pandemic and the shift of police and first-responder interventions.

Although botulinum toxin does not have regulatory approval for the treatment of depression in the United States, some reports indicate neurotoxin treatment may mitigate symptoms.

Research zeroes in on how frailty impacts depression treatment in elderly patients.

Unemployment is associated with an array of social and psychological complexities, directly affecting patients' self-esteem and perceptions of self-worth. When a patient loses their job, the psychiatrist has 4 tasks.

If a picture is worth a thousand words, how many diagnoses can it make? The photographer and psychiatrist Hugh Welch Diamond, MD, shares insights into the humanity and stigma of mental illness in Victorian England.

Preliminary studies suggest that adjuvant treatment with a statin may be beneficial for patients who are also prescribed psychotropic drugs for depression and schizophrenia.

The most common emergency presentations to emergency departments are identified.

What is the most abundant and ubiquitous neurotransmitter in the mammalian central nervous system?

There is much to look forward to in the realm of improved treatments for patients with psychiatric illness.

Strategies for educating patients on COVID-19 transmission and epidemiology, as well as dispelling myths

Axsome Therapeutics released details from their COMET-SI trial for AXS-05, an oral investigational NMDA receptor.

As typically happens in the aftermath of suicide—years or even decades later—we wonder what we could have said or should have seen.

Are patients with depression and substance use disorder getting an appropriate level of care? Our Journal Club piece investigates.

The PHQ-9 may be an effective asset in a clinician’s toolkit, along with their clinical judgment and therapeutic alliance, to ensure treatment planning and outcome tracking is personal to each patient.

Physical activity and exercise are recognized as fundamental tools for reducing the impact of chronic diseases, including depression.

Facts and myths about depression during the holidays.

What issues do you anticipate your patients will struggle with during the upcoming holidays?

Patients' first reactions to a diagnosis of major depressive disorder can be varied. What can you do to help them cope?

Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.

There are no human clinical trials or even case reports to assess or describe the efficacy of this very complex botanical. Here’s what we know.

With the state of the world, there are so many difficult conversations about racism, hatred, and violence that we need to have with our children.

Oxcarbazepine might be considered for patients who you want to treat with carbamazepine for mania (as monotherapy or adjunct) but for whom it would be unsafe or who have been unable to tolerate it.

We have learned that in order to provide much-needed social support during difficult times, organizations should prepare to take certain steps.

The physical and psychological symptoms of anxiety, such as feeling tense or having trouble concentrating, can be so uncomfortable that they cause behavioral changes. How might these components play out in, say, a Presidential election?

Read about the new results from Sage’s clinical study of depression treatment, zuranolone.

There are epidemiological and clinical reasons why we should drop that term.

Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.